Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (16337)	3/3/1998 3:33:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Speaking of non-scientific explanations, I just talked to IR and it sounds like the wires will stay hot. For "March Madness" the NDA is still "on track" for filing this month. In addition, LGND will be presenting at Raymond James on March 19-20 (maybe they can get them to pick up coverage again), and TSE424 is still slated to enter the clinic this month (and it will be accompanied by a press release because the IND will trigger a milestone payment from AHP). An announcement of the LLY option should come out "soon". There are three possibilities (compound, cash, or extension). To cap off March, LGND may actually have their own web site up! In the beginning of April (4-6) Ligand will be presenting at an AIDS conference which include final or near final Phase II oral Panretin and the data looks "very good". Also in April LGND will be presenting at UBS in Europe. In May LGND will have two presentations at ASCO. One will be safety data on LGD1550 and a small amount of efficacy data. However, the AIDS consortium will be reporting on their Phase II data on Panretin oral. The initial Phase II data showed 36% and 37% and I suspect that the presentations will be on close to final data which will be as good or better. LGND is seriously considering taking the two studies and go straight into an NDA filing, which would mean that they would have a shot at 4 NDAs this year! In May LGND will also be presenting at H&Q in London. In June/July LGND will be presenting big time at the International AIDS conference in Geneva. There may be 3 (or 4?) presentations (2 oral and a topical presentation for KS). In addition to the above, there are Phase II data on Targretin for Prostate, Psoriasis, Diabetes, and the start of Breast (not sure if its montherapy or in combination with Tamoxifen), as well as Panretin data for Breast (mono therapy as well as combination with Panretin which LGND calls Phase I/II) and psoriasis, and ovarian? as well as IND filings by ABT, GLX, and LLY (LLY is an IND for second generation Rexinoid as well as the start of type II diabetes for Targretin). Leptin is still unknown and I didn't ask about new coverage. AGN filings are also still unknown. I didn't ask about Targretin Oral and Topical for CTCL, but assume that they are also on track, so this year should stay very busy.